Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-30
2009-02-17
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S398000, C548S312100
Reexamination Certificate
active
07491743
ABSTRACT:
The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.
REFERENCES:
patent: 4110536 (1978-08-01), Havera et al.
patent: 4332952 (1982-06-01), Schnur
patent: 4837165 (1989-06-01), Hawke
patent: 5693643 (1997-12-01), Gilbert et al.
patent: 6756394 (2004-06-01), Yuan et al.
patent: 6797708 (2004-09-01), McKew et al.
patent: 0343643 (1994-03-01), None
patent: 1275646 (2003-01-01), None
patent: 2080803 (1982-02-01), None
patent: 02019363 (1990-01-01), None
patent: WO 92/04045 (1992-03-01), None
patent: WO 96/30393 (1996-10-01), None
patent: WO 98/39303 (1998-09-01), None
patent: WO 01/28493 (2001-04-01), None
patent: WO 01/85718 (2001-11-01), None
patent: WO 04/070050 (2004-08-01), None
Havera et al., 1979, CAS: 90: 121596.
Horwell et al., 1992, CAS: 117:84251.
Becker et al., 1996, CAS : 125 :327717.
Borner et al., “Apoptosis Without Caspases: An Inefficient Molecular Guillotine?”Cell Death Differ. 6:497-507 (1999).
Buyukbingol et al., “Studies on the Synthesis and Structure-Activity Relationships of 5-(3′-indolal)-2-Thiohydantoin Derivatives as Aldose Reductase Enzyme Inhibitors,”Farmaco49:443-447 (1994).
Chi et al., “Oncogenic Ras Triggers Cell Suicide Through the Activation of a Caspase- Independent Cell Death Program in Human Cancer Cells,”Oncogene18: 2281-2290 (1999).
Cryns et al., “Proteases to Die For,”Genes&Develop. 12:1551-1570 (1978).
Degterev et al., “Chemical Inhibitor of Nonapoptotic Cell Death With Therapeutic Potential for Ischemic Brain Injury,”Nat. Chem. Biol. 1:112-119 (2005).
Edman, “Method for Determination of the Amino Acid Sequence in Peptides,”Acta Chem. Scand. 4:283-293 (1950).
Eldadah et al., “Caspase Pathways, Neuronal Apoptosis, and CNS Injury,”J. Neurotrauma17:811-829 (2000).
Fiers et al., “More Than One Way to Die: Apoptosis, Necrosis and Reactive Oxygen Damage,”Oncogene18:7719-7730 (1999).
Fujiwara et al., “13C Nuclear Magnetic Resonance Studies on the Conformation of Substituted Hydantoins,”J. Chemical Soc. Perkin2:1573-1577 (1980).
Hara et al., “Inhibition of Interleukin 1beta Converting Enzyme Family Proteases Reduces Ischemic and Excitotoxic Neuronal Damage,”Proc Natl Acad Sci U.S.A. 94:2007-2012 (1997).
Herceg et al., “Failure of Poly(ADP-ribose) Polymerase Cleavage by Caspases Leads to Induction of Necrosis and Enhanced Apoptosis,”Mol Cell Biol. 19:5124-5133 (1999).
Hirsch et al., “The Apoptosis-Necrosis Paradox, Apoptogenic Proteases Activated After Mitochondrial Permeability Transition Determine the Mode of Cell Death,”Oncogene15:1573-1581 (1997).
Holler et al., “Fas Triggers an Alternative, Caspase-8-Independent Cell Death Pathway Using the Kinase RIP as Effector Molecule,”Nature Immunol. 1:489-495 (2000).
Inglis et al., “The identification of tryptophan residues in proteins as oxidised derivatives during amino acid sequence determinations,”FEBS Letters104:115-118 (1979).
Janin et al., “Methyl Orthocarboxylates as Methylating Agents of Heterocycles,”Eur. J. Org. Chem. 1763-1769 (2002).
Kaul et al., “Pathways to Neuronal Injury and Apoptosis in HIV-Associated Dementia,”Nature410:988-994 (2001).
Kawahara et al., “Caspase-Independent Cell Killing by Fas-Associated Protein With Death Domain,”J. Cell Biol. 143:1353-1360 (1998).
Khwaja et al., “Resistance to the Cytotoxic Effects of Tumor Necrosis Factor Alpha can be Overcome by Inhibition of a FADD/Caspase-Dependent Signaling Pathway,”J. Biol. Chem. 274:36817-36823 (1999).
Kitanaka et al., “Caspase-Independent Programmed Cell Death With Necrotic Morphology,”Cell Death Differ. 6:508-515 (1999).
Leist et al., “Inhibition of Mitochondrial ATP Generation by Nitric Oxide Switches Apoptosis to Necrosis,”Exp. Cell Res. 249:396-403 (1999).
Lewis et al., “Tryptophan-Derived NK1 Antagonists: Conformationally Constrained Heterocyclic Bioisosteres of the Ester Linkage,”J. Med. Chem. 38:923-933 (1995).
Li et al., “Induction of Necrotic-Like Cell Death by Tumor Necrosis Factor Alpha and Caspase Inhibitors: Novel Mechanism for Killing Virus-Infected Cells,”J. Virol. 74:7470-7477 (2000).
Luschen et al., “Sensitization to Death Receptor Cytotoxicity by Inhibition of Fas-Associated Death Domain Protein (FADD)/Caspase Signaling. Requirement of Cell Cycle Progression,”J. Biol. Chem. 275:24670-24678 (2000).
Martin et al., “Neurodegeneration in Excitotoxicity, Global Cerebral Ischemia, And Target Deprivation: A Perspective on the Contributions of Apoptosis and Necrosis,”Brain Res. Bull. 46:281-309 (1998).
Matsumura et al., “Necrotic Death Pathway in Fas Receptor Signaling,”J. Cell Biol. 151:1247-1255 (2000).
McCarthy et al., “Inhibition of Ced-3/ICE-Related Proteases Does Not Prevent Cell Death Induced by Oncogenes, DNA Damage, or the Bcl-2 Homologue Bak,”J. Cell Biol. 136:215-227 (1997).
McMurray, “Huntington's Disease: New Hope for Therapeutics,”Trends Neurosci. 24:S32-S38 (2001).
Molina et al., “A Simple and General Entry to Aplysinopsine-Type Alkaloids by Tandem Aza-Wittig/Heterocumulene-Mediated Annelation,”Tet Lett. 33:4491-4494 (1992).
Nicotera et al., “Apoptosis and Necrosis: Different Execution of the Same Death,”Biochem. Soc. Symp. 66:69-73 (1999).
Park et al., “Diastereoselective Synthesis of Hydantoin- and Isoxazoline-Substituted Dispirocyclobutanoids,”J. Org. Chem. 65:3520-3524 (2000).
Polverino et al., “Selective Activation of Capases During Apoptotic Induction in HL-60 Cells,”J. Biol. Chem. 272:7013-7021 (1997).
Raghupathi et al., “Apoptosis After Traumatic Brain Injury,”J. Neurotrauma17:927-938 (2000).
Sané et al., “Caspase Inhibition in Camptothecin-Treated U-937 Cells is Coupled With a Shift from Apoptosis to Transient G1 Arrest Followed by Necrotic Cell Death,”Cancer Res. 59:3565-3569 (1999).
Selkoe, “Translating Cell Biology Into Therapeutic Advances in Alzheimer's Disease,”Nature399:A23-A31 (1999).
Syntichaki et al., “Death by Necrosis. Uncontrollable Catastrophe, Or is There Order Behind the Chaos?”EMBO Rep. 3:604-609 (2002).
Takahashi et al., “Antimutagenic Properties of 3, 5-Disubstituted 2-Thiohydantoins,”J. Agric. Food Chem. 46:5037-5042 (1998).
Talanian et al., “Caspases as Targets for Anti-Inflammatory and Anti-Apoptotic Drug Discovery,”J. Med. Chem. 43:3351-3371 (2000).
Teng et al., “Structure-Activity Relationship Study of Novel Necroptosis Inhibitors,”Bioorg. Med. Chem. Lett. 15:5039-5044 (2005).
Vercammen et al., “Dual Signaling of the Fas Receptor: Initiation of Both Apoptotic and Necrotic Cell Death Pathways,”J. Exp. Med. 188:919-930 (1998).
Vercammen et al., “Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor,”J. Exp. Med. 187:1477-1485 (1998).
Vila et al., “Engineered modeling and the secrets of Parkinson's disease,”Trends Neurosci. 24:S49-S55 (2001).
Waterfield et al., “Amino Acid Sequence Analysis with Methyl Isothiocyanate Resolution of the Methylthiohydantoins by Gas- Liquid Partition Chromatography,”Biochemistry9:832-839 (1970).
Woo, “Gas-Chromatographic Determination of Methylthiohydantoin Amino Acid as N(O)-Butyldimethylsilyl Derivatives in Amino Acid Sequencing with Methylisothiocyanate,”J. Korean Agric. Chem. Soc. 35:132-138 (1992).
Wyllie et al., “Cell Death: The Significance of Apoptosis,”Int. Rev. Cytol. 68:251-3
Cuny Gregory D.
Degterev Alexei
Jagtap Prakash
Yuan Junying
Bieker-Brady Kristina
Clark & Elbing LLP
President and Fellows of Harvard College
Shiao Rei-tsang
The Brigham and Women's Hospital, Inc.
LandOfFree
Inhibitors of cellular necrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of cellular necrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of cellular necrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092251